ATE421502T1 - Calciumkanalantagonisten vom n-typ zur behandlung von schmerzen - Google Patents

Calciumkanalantagonisten vom n-typ zur behandlung von schmerzen

Info

Publication number
ATE421502T1
ATE421502T1 AT01981242T AT01981242T ATE421502T1 AT E421502 T1 ATE421502 T1 AT E421502T1 AT 01981242 T AT01981242 T AT 01981242T AT 01981242 T AT01981242 T AT 01981242T AT E421502 T1 ATE421502 T1 AT E421502T1
Authority
AT
Austria
Prior art keywords
pain
treatment
type calcium
calcium channel
channel antagonists
Prior art date
Application number
AT01981242T
Other languages
English (en)
Inventor
Marc Chapdelaine
Lucius Kemp
John Mccauley
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE421502T1 publication Critical patent/ATE421502T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01981242T 2000-11-06 2001-10-31 Calciumkanalantagonisten vom n-typ zur behandlung von schmerzen ATE421502T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0004056A SE0004056D0 (sv) 2000-11-06 2000-11-06 N-type calcium channel antagonists for the treatment of pain

Publications (1)

Publication Number Publication Date
ATE421502T1 true ATE421502T1 (de) 2009-02-15

Family

ID=20281716

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01981242T ATE421502T1 (de) 2000-11-06 2001-10-31 Calciumkanalantagonisten vom n-typ zur behandlung von schmerzen

Country Status (9)

Country Link
US (1) US6841680B2 (de)
EP (1) EP1339690B1 (de)
JP (1) JP2004513118A (de)
AT (1) ATE421502T1 (de)
AU (1) AU2002212897A1 (de)
DE (1) DE60137534D1 (de)
ES (1) ES2319259T3 (de)
SE (1) SE0004056D0 (de)
WO (1) WO2002036569A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862301B1 (fr) * 2003-11-17 2007-12-21 Aventis Pharma Sa Nouveau procede de preparation de quinoleines 3-fluorees
JP2008534630A (ja) * 2005-04-08 2008-08-28 ニューロメッド ファーマシューティカルズ リミテッド 疼痛の軽減のためのn型カルシウムチャネルブロッカーを含む組み合わせ治療の方法
US8362021B2 (en) * 2006-05-11 2013-01-29 Zalicus Pharmaceuticals Ltd. Method for increasing the bioavailability of benzhydryl piperazine containing compounds
RU2627694C2 (ru) 2010-10-29 2017-08-10 Клино Лтд. Производные хинолина, визуализирующий белок тау
US8409560B2 (en) 2011-03-08 2013-04-02 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
US8591944B2 (en) 2011-03-08 2013-11-26 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
DE102016125645A1 (de) * 2016-12-23 2018-06-28 Forschungszentrum Jülich GmbH D-enantiomere Peptide zur Therapie von chronischem und neuropathischem Schmerz

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2114727C (en) * 1991-08-02 1996-12-10 Mikel P. Moyer Quinoline derivatives as immunostimulants

Also Published As

Publication number Publication date
SE0004056D0 (sv) 2000-11-06
EP1339690A1 (de) 2003-09-03
US6841680B2 (en) 2005-01-11
DE60137534D1 (de) 2009-03-12
WO2002036569A1 (en) 2002-05-10
EP1339690B1 (de) 2009-01-21
ES2319259T3 (es) 2009-05-06
AU2002212897A1 (en) 2002-05-15
US20040053965A1 (en) 2004-03-18
JP2004513118A (ja) 2004-04-30

Similar Documents

Publication Publication Date Title
ATE323693T1 (de) Calciumkanalantagonisten vom n-typ zur behandlung von schmerzen
DE60113496D1 (de) Verwendung von Glycyrrhizin zur Behandlung von Mastitis.
ATE407676T1 (de) Topoisomerasehemmern zur behandlung von chirurgischen verklebungen
ATE250576T1 (de) Substituierte pyrrolylverbindungen zur behandlung von entzündungen
DE60117977D1 (de) Vorrichtungen zur behandlung von harninkontinenz
ES2151599T3 (es) Acidos hidroxamicos substituidos con arilsulfonamido como inhibidores de matriz metaloproteinasas.
SE9900100D0 (sv) New compounds
ATE320257T1 (de) (s,s)-reboxetine zur behandlung chronischer schmerzen
DE69917957D1 (de) Blockcopolymerzusammensetzung für die Modifikation von Asphalt, und Asphaltzusammensetzung enthaltend diese Blockcopolymerzusammensetzung
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE60101354T2 (de) Diorganopolysiloxan/Acrylat-Copolymer enthaltende Emulsionen zur Behandlung von Flächengebilden
ATE295837T1 (de) Antagonisten für calciumkanäle vom n-typ zur behandlung von schmerzen
DE60136397D1 (de) Konjugiertes Dienkautschukgel, Kautschukzusammensetzungen die dieses enthalten und Verfahren zur Herstellung von konjugiertem Dienkautschuk
DE69913548D1 (de) Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60216495D1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
ATE381938T1 (de) Verwendungen zur behandlung von fsh-verbundenen zuständen mit gnrh antagonisten
SE0004054D0 (sv) N-type calcium channel antagonists for the treatment of pain
DE60139195D1 (de) Aktivierbare polymerzusammensetzung, und gegenstände, die diese nutzen
ATE421502T1 (de) Calciumkanalantagonisten vom n-typ zur behandlung von schmerzen
ATE259791T1 (de) N-alkyl-ammonium-acetonitril-salze, methoden dazu und zusammensetzungen die diese enthalten
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
SE0004055D0 (sv) N-type calcium channel antagonists for the treatment of pain

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties